Blog Category:

Bridging Gaps and Advancing Care in Sickle Cell Disease in the Context of Drug Therapy

Sickle cell disease (SCD) is a pathology caused by a mutative hemoglobin protein that produces rigid, sickle-shaped red blood cells (RBCs). Lifelong complications of SCD include acute veno-occlusive crises (VOCs), whose recurrence takes a significant toll on patients, and end-organ …

Livestream: IBD, IL-23, and Inflammation, Oh My! Following the Yellow Brick Road in Using IL-23 Targeted Therapies in Managing IBD

Significant therapeutic advancements have been made over the last decade for treatment of inflammatory bowel disease (IBD), a chronic condition that includes Crohn’s disease (CD) and ulcerative colitis (UC). The inflammatory cytokine interleukin (IL)-23 has been established as an active …

Diagnostic and Therapeutic Advances in Primary Biliary Cholangitis: Maximizing Opportunities to Improve Patient Care and Outcomes

Primary biliary cholangitis (PBC) is a chronic autoimmune disease of the intrahepatic bile ducts that is often misdiagnosed until it progresses to advanced stages, including end-stage liver disease.  Symptoms such as intractable pruritus and severe fatigue, often accompanied by abnormal …

Who, What, and Why of Biomarker Testing in Ovarian Cancer

Recent advances in the treatment of gynecologic cancers are promising, and education is needed to ensure that both oncology and primary care clinicians, including OB/GYNs, have a thorough knowledge of biomarkers, current and emerging therapies, and how the latest clinical …

Taking the Mystery Out of the Mycophenolate Pregnancy Registry

The Mycophenolate Pregnancy Registry was introduced to assess risks and outcomes associated with mycophenolate use during pregnancy – a situation that occurs far too often, despite boxed warnings and an ongoing REMS program.    

In this second of two, interactive …

Stepping Up Counseling for Patients of Childbearing Potential Taking Mycophenolate

The Mycophenolate Risk Evaluation and Mitigation Strategy (MREMS) was initiated in 2012, yet more than a decade later prenatal exposure to mycophenolate, an immunosuppressive agent with significant teratogenicity, continues to occur at unacceptably high rates. While the MREMS provides direction …

IBD, IL-23, and Inflammation, Oh My! Following the Yellow Brick Road in Using IL-23 Targeted Therapies in Managing IBD

Significant therapeutic advancements have been made over the last decade for treatment of inflammatory bowel disease (IBD), a chronic condition that includes Crohn’s disease (CD) and ulcerative colitis (UC). The inflammatory cytokine interleukin (IL)-23 has been established as an active …

Nourishing Communities Part 2: Tackling Health Disparities Through Accessible Food Resources

Food insecurity and nutritional inequity disproportionately impact underserved communities. These disparities are directly linked to higher rates of chronic diseases, such as obesity, diabetes, and cardiovascular diseases. Research shows that access to healthy food is limited in food deserts, exacerbating …

Nourishing Communities Part 3: Screening and Intervention to Improve Nutrition Equity in Underserved Communities

Food insecurity and other negative social drivers of health (SDOH) impact health outcomes in underserved Black communities. Screening for food insecurity using validated tools has proven to be an essential part of healthcare interventions to connect patients to critical resources, …